Search NLS News

Just ten years ago it was hard to predict the progress that has been made within the field of cancer therapy. A cancer vaccine, including a universal cancer vaccine, as the ultimate goal is for many the holy grail, and several Norwegian companies are paving the way. Cancer accounted for nearly ten million deaths in […]

Recipharm has announced the appointment of Vikas Gupta as President of its recently renamed biologics business unit, ReciBioPharm. This appointment comes as Recipharm officially renames its biologics business unit following the acquisitions of advanced therapy CDMO, Arranta Bio; GenIbet, a specialist in the manufacture of biological clinical material; and virotherapy CDMO, Vibalogics. “Vikas has a […]

An international team of researchers has identified the first genetic variant associated with disease severity in multiple sclerosis (MS). In MS, the immune system mistakenly attacks the brain and spinal cord, resulting in symptom flares known as relapses as well as longer-term degeneration, known as progression. Previous studies have identified genetic factors that increase the risk […]

The United Kingdom’s decision to leave the European Union sent shockwaves across industries, including the life sciences sector. Many companies are grappling with uncertainty and are still struggling to understand the potential implications of Brexit on their operations. Despite this, some opportunities may arise, particularly for the Nordic region, which has close links with the […]

After many years of technical challenges and disappointing results, gene therapy is starting to gain real ground and holds promise within several diseases, ranging from blindness to cancer.

In June the board of Abera Bioscience announced that it has decided to reorganize the company in order to facilitate financing and collaborations for the various vaccine projects. Abera develops vaccines and immunotherapies based on its patented platforms. The lead project is a nasal vaccine against pneumococcus which is being prepared for phase I. The […]

We would like to thank our readers, subscribers and collaboration partners for a fruitful and eventful Q1 + Q2 2023, and we wish you all a most wonderful summer! The next NLS Newsletter will be sent out on August 10, but our news feed and social media channels will continue to provide you with the […]

BioArctic’s partner Eisai has announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application, sBLA, supporting the traditional approval of LEQEMBI 100 mg/mL injection for intravenous use. This approval makes LEQEMBI the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and […]

The global pharma company has announced an investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival. This includes new or expanded projects in Brazil, India, Vietnam, Ghana and Rwanda that will contribute to the company’s climate action, restore nature, promote biodiversity and […]

Several discussions regarding reverse acquisitions have taken place, but with no successful outcome. The sale of the technology platform did not receive bids valued at a level required to continued operation, states the company in a press release. Despite diligent and continuous effort up until the day of filing for bankruptcy, Idogen has been unsuccessful […]